JWH-007

File:JWH-007.svg

JWH-007.svg

JWH-007 is a synthetic cannabinoid that was developed in the early 2000s by John W. Huffman and his team at Clemson University. It is part of the naphthoylindole family of synthetic cannabinoids, which are known for their high affinity for the CB1 receptor and CB2 receptor in the endocannabinoid system.

Chemical Structure and Properties

JWH-007 has the chemical formula C23H21NO and a molecular weight of 327.42 g/mol. Its structure includes a naphthoyl group attached to an indole core, which is a common feature among many synthetic cannabinoids. The full IUPAC name for JWH-007 is 1-pentyl-3-(1-naphthoyl)indole.

Pharmacology

JWH-007 acts as a potent agonist at both the CB1 receptor and CB2 receptor, with a higher affinity for the CB1 receptor. This interaction with the endocannabinoid system results in effects that are similar to those produced by tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. These effects can include analgesia, euphoria, and altered perception.

Legal Status

The legal status of JWH-007 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. For example, in the United States, JWH-007 is listed as a Schedule I controlled substance under the Controlled Substances Act.

Potential Risks and Side Effects

As with other synthetic cannabinoids, the use of JWH-007 can pose significant health risks. These may include tachycardia, hypertension, anxiety, paranoia, and hallucinations. There have also been reports of more severe adverse effects such as seizures and acute kidney injury.

Research and Applications

While JWH-007 and other synthetic cannabinoids have been used in scientific research to better understand the endocannabinoid system, their recreational use has raised concerns among health professionals and regulatory agencies. Research continues to explore the potential therapeutic applications of cannabinoids, but the non-medical use of synthetic variants like JWH-007 remains controversial.

See Also

• Synthetic cannabinoids
• John W. Huffman
• CB1 receptor
• CB2 receptor
• Endocannabinoid system
• Controlled Substances Act